FDA finalizes guidance on prescription drug use-related software, pharma rejoices

The Food and Drug Administration has finalized guidance governing prescription drug use-related software, according to STAT News. The outlet’s Health Tech coverage, published October 22, reports that the pharmaceutical industry has welcomed the finalized rules.

The same dispatch covers a second development in parallel: telehealth providers are promoting GLP-1 medications as treatments for addiction. STAT groups both items under its Health Tech vertical, pairing a regulatory story with a clinical-practice story in the same roundup.

The guidance concerns what STAT terms “prescription drug use-related software,” a category describing applications and digital tools tied to the administration or monitoring of prescription medications. The finalization follows a rulemaking process at the agency, though the available summary does not specify the guidance’s provisions beyond its subject and the industry reaction it drew.

STAT’s framing links the two stories as snapshots of a shifting landscape where software, pharmaceuticals, and remote prescribing increasingly intersect. The outlet does not elaborate, in the material reviewed here, on which companies or drug classes fall under the new software guidance, nor on the scale of telehealth GLP-1 prescribing for addiction treatment.

Readers seeking the underlying provisions and sourcing are directed to the full STAT+ dispatch, published October 22, 2026.